Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumor tends to occur at an earlier than average age, individuals may have more than one primary tumor, the tumors may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.
Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing.
An educational process that provides information and advice to individuals or families about a genetic condition that may affect them. The purpose is to help individuals make informed decisions about marriage, reproduction, and other health management issues based on information about the genetic disease, the available diagnostic tests, and management programs. Psychosocial support is usually offered.
Tumors or cancer of the human BREAST.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
A characteristic symptom complex.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
An individual having different alleles at one or more loci regarding a specific character.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
A phenomenon that is observed when a small subgroup of a larger POPULATION establishes itself as a separate and isolated entity. The subgroup's GENE POOL carries only a fraction of the genetic diversity of the parental population resulting in an increased frequency of certain diseases in the subgroup, especially those diseases known to be autosomal recessive.
Biochemical identification of mutational changes in a nucleotide sequence.
The health status of the family as a unit including the impact of the health of one member of the family on the family as a unit and on individual family members; also, the impact of family organization or disorganization on the health status of its members.
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.
The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
A cell line derived from cultured tumor cells.
Surgical procedure to remove one or both breasts.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
DNA present in neoplastic tissue.
Pathological processes of the BREAST.

RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. (1/13)

 (+info)

The impact of risk information exposure on women's beliefs about direct-to-consumer genetic testing for BRCA mutations. (2/13)

 (+info)

Germline DNA copy number variation in familial and early-onset breast cancer. (3/13)

INTRODUCTION: Genetic factors predisposing individuals to cancer remain elusive in the majority of patients with a familial or clinical history suggestive of hereditary breast cancer. Germline DNA copy number variation (CNV) has recently been implicated in predisposition to cancers such as neuroblastomas as well as prostate and colorectal cancer. We evaluated the role of germline CNVs in breast cancer susceptibility, in particular those with low population frequencies (rare CNVs), which are more likely to cause disease." METHODS: Using whole-genome comparative genomic hybridization on microarrays, we screened a cohort of women fulfilling criteria for hereditary breast cancer who did not carry BRCA1/BRCA2 mutations. RESULTS: The median numbers of total and rare CNVs per genome were not different between controls and patients. A total of 26 rare germline CNVs were identified in 68 cancer patients, however, a proportion that was significantly different (P = 0.0311) from the control group (23 rare CNVs in 100 individuals). Several of the genes affected by CNV in patients and controls had already been implicated in cancer. CONCLUSIONS: This study is the first to explore the contribution of germline CNVs to BRCA1/2-negative familial and early-onset breast cancer. The data suggest that rare CNVs may contribute to cancer predisposition in this small cohort of patients, and this trend needs to be confirmed in larger population samples.  (+info)

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. (4/13)

INTRODUCTION: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2). METHODS: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework. RESULTS: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 x 10-4). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 x 10-5, P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 x 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049). CONCLUSIONS: The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers.  (+info)

Methodological quality of English-language genetic guidelines on hereditary breast-cancer screening and management: an evaluation using the AGREE instrument. (5/13)

 (+info)

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer. (6/13)

 (+info)

Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. (7/13)

 (+info)

Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. (8/13)

 (+info)

Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a genetic condition caused by variants in the BRCA1 and BRCA2 genes, among others. These gene mutations increase the risk of developing breast cancer, ovarian cancer, and several other types of cancer.

In HBOC, an individual has a 50-85% chance of developing breast cancer and a 10-40% chance of developing ovarian cancer by age 70. Men with HBOC also have an increased risk of breast cancer, prostate cancer, and pancreatic cancer. The syndrome can be passed down through generations in families, with each child of an affected parent having a 50% chance of inheriting the mutated gene. Genetic testing is available to identify individuals who carry these mutations and help guide their medical management.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

BRCA1 (BReast CAncer gene 1) is a tumor suppressor gene that produces a protein involved in repairing damaged DNA and maintaining genetic stability. Mutations in the BRCA1 gene are associated with an increased risk of developing hereditary breast and ovarian cancers. Inherited mutations in this gene account for about 5% of all breast cancers and about 10-15% of ovarian cancers. Women who have a mutation in the BRCA1 gene have a significantly higher risk of developing breast cancer and ovarian cancer compared to women without mutations. The protein produced by the BRCA1 gene also interacts with other proteins to regulate cell growth and division, so its disruption can lead to uncontrolled cell growth and tumor formation.

BRCA2 (pronounced "braca two") protein is a tumor suppressor protein that plays a crucial role in repairing damaged DNA in cells. It is encoded by the BRCA2 gene, which is located on chromosome 13. Mutations in the BRCA2 gene have been associated with an increased risk of developing certain types of cancer, particularly breast and ovarian cancer in women, and breast and prostate cancer in men.

The BRCA2 protein interacts with other proteins to repair double-strand breaks in DNA through a process called homologous recombination. When the BRCA2 protein is not functioning properly due to a mutation, damaged DNA may not be repaired correctly, leading to genetic instability and an increased risk of cancer.

It's important to note that not all people with BRCA2 mutations will develop cancer, but their risk is higher than those without the mutation. Genetic testing can identify individuals who have inherited a mutation in the BRCA2 gene and help guide medical management and screening recommendations.

BRCA1 protein is a tumor suppressor protein that plays a crucial role in repairing damaged DNA and maintaining genomic stability. The BRCA1 gene provides instructions for making this protein. Mutations in the BRCA1 gene can lead to impaired function of the BRCA1 protein, significantly increasing the risk of developing breast, ovarian, and other types of cancer.

The BRCA1 protein forms complexes with several other proteins to participate in various cellular processes, such as:

1. DNA damage response and repair: BRCA1 helps recognize and repair double-strand DNA breaks through homologous recombination, a precise error-free repair mechanism.
2. Cell cycle checkpoints: BRCA1 is involved in regulating the G1/S and G2/M cell cycle checkpoints to ensure proper DNA replication and cell division.
3. Transcription regulation: BRCA1 can act as a transcriptional co-regulator, influencing the expression of genes involved in various cellular processes, including DNA repair and cell cycle control.
4. Apoptosis: In cases of severe or irreparable DNA damage, BRCA1 helps trigger programmed cell death (apoptosis) to eliminate potentially cancerous cells.

Individuals with inherited mutations in the BRCA1 gene have a higher risk of developing breast and ovarian cancers compared to the general population. Genetic testing for BRCA1 mutations is available for individuals with a family history of these cancers or those who meet specific clinical criteria. Identifying carriers of BRCA1 mutations allows for enhanced cancer surveillance, risk reduction strategies, and potential targeted therapies.

BRCA2 is a specific gene that provides instructions for making a protein that helps suppress the growth of cells and plays a crucial role in repairing damaged DNA. Mutations in the BRCA2 gene are known to significantly increase the risk of developing breast cancer, ovarian cancer, and several other types of cancer.

The BRCA2 protein is involved in the process of homologous recombination, which is a type of DNA repair that occurs during cell division. When DNA is damaged, this protein helps to fix the damage by finding a similar sequence on a sister chromatid (a copy of the chromosome) and using it as a template to accurately repair the break.

If the BRCA2 gene is mutated and cannot produce a functional protein, then the cell may not be able to repair damaged DNA effectively. Over time, this can lead to an increased risk of developing cancer due to the accumulation of genetic alterations that cause cells to grow and divide uncontrollably.

It's worth noting that while mutations in the BRCA2 gene are associated with an increased risk of cancer, not everyone who has a mutation will develop cancer. However, those who do develop cancer tend to have an earlier onset and more aggressive form of the disease. Genetic testing can be used to identify mutations in the BRCA2 gene, which can help inform medical management and screening recommendations for individuals and their families.

Hereditary neoplastic syndromes refer to genetic disorders that predispose affected individuals to develop tumors or cancers. These syndromes are caused by inherited mutations in specific genes that regulate cell growth and division. As a result, cells may divide and grow uncontrollably, leading to the formation of benign or malignant tumors.

Examples of hereditary neoplastic syndromes include:

1. Hereditary breast and ovarian cancer syndrome (HBOC): This syndrome is caused by mutations in the BRCA1 or BRCA2 genes, which increase the risk of developing breast, ovarian, and other cancers.
2. Lynch syndrome: Also known as hereditary non-polyposis colorectal cancer (HNPCC), this syndrome is caused by mutations in DNA mismatch repair genes, leading to an increased risk of colon, endometrial, and other cancers.
3. Li-Fraumeni syndrome: This syndrome is caused by mutations in the TP53 gene, which increases the risk of developing a wide range of cancers, including breast, brain, and soft tissue sarcomas.
4. Familial adenomatous polyposis (FAP): This syndrome is caused by mutations in the APC gene, leading to the development of numerous colon polyps that can become cancerous if not removed.
5. Neurofibromatosis type 1 (NF1): This syndrome is caused by mutations in the NF1 gene and is characterized by the development of benign tumors called neurofibromas on the nerves and skin.
6. Von Hippel-Lindau disease (VHL): This syndrome is caused by mutations in the VHL gene, leading to an increased risk of developing various types of tumors, including kidney, pancreas, and adrenal gland tumors.

Individuals with hereditary neoplastic syndromes often have a higher risk of developing cancer than the general population, and they may require more frequent screening and surveillance to detect cancers at an early stage when they are more treatable.

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. For example, a physician may recommend genetic testing to help diagnose a genetic condition, confirm the presence of a gene mutation known to increase the risk of developing certain cancers, or determine the chance for a couple to have a child with a genetic disorder.

There are several types of genetic tests, including:

* Diagnostic testing: This type of test is used to identify or confirm a suspected genetic condition in an individual. It may be performed before birth (prenatal testing) or at any time during a person's life.
* Predictive testing: This type of test is used to determine the likelihood that a person will develop a genetic disorder. It is typically offered to individuals who have a family history of a genetic condition but do not show any symptoms themselves.
* Carrier testing: This type of test is used to determine whether a person carries a gene mutation for a genetic disorder. It is often offered to couples who are planning to have children and have a family history of a genetic condition or belong to a population that has an increased risk of certain genetic disorders.
* Preimplantation genetic testing: This type of test is used in conjunction with in vitro fertilization (IVF) to identify genetic changes in embryos before they are implanted in the uterus. It can help couples who have a family history of a genetic disorder or who are at risk of having a child with a genetic condition to conceive a child who is free of the genetic change in question.
* Pharmacogenetic testing: This type of test is used to determine how an individual's genes may affect their response to certain medications. It can help healthcare providers choose the most effective medication and dosage for a patient, reducing the risk of adverse drug reactions.

It is important to note that genetic testing should be performed under the guidance of a qualified healthcare professional who can interpret the results and provide appropriate counseling and support.

Genetic counseling is a process of communication and education between a healthcare professional and an individual or family, aimed at understanding, adapting to, and managing the medical, psychological, and familial implications of genetic contributions to disease. This includes providing information about the risk of inherited conditions, explaining the implications of test results, discussing reproductive options, and offering support and resources for coping with a genetic condition. Genetic counselors are trained healthcare professionals who specialize in helping people understand genetic information and its impact on their health and lives.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

A germ-line mutation is a genetic change that occurs in the egg or sperm cells (gametes), and thus can be passed down from parents to their offspring. These mutations are present throughout the entire body of the offspring, as they are incorporated into the DNA of every cell during embryonic development.

Germ-line mutations differ from somatic mutations, which occur in other cells of the body that are not involved in reproduction. While somatic mutations can contribute to the development of cancer and other diseases within an individual, they are not passed down to future generations.

It's important to note that germ-line mutations can have significant implications for medical genetics and inherited diseases. For example, if a parent has a germ-line mutation in a gene associated with a particular disease, their offspring may have an increased risk of developing that disease as well.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

The breast is the upper ventral region of the human body in females, which contains the mammary gland. The main function of the breast is to provide nutrition to infants through the production and secretion of milk, a process known as lactation. The breast is composed of fibrous connective tissue, adipose (fatty) tissue, and the mammary gland, which is made up of 15-20 lobes that are arranged in a radial pattern. Each lobe contains many smaller lobules, where milk is produced during lactation. The milk is then transported through a network of ducts to the nipple, where it can be expressed by the infant.

In addition to its role in lactation, the breast also has important endocrine and psychological functions. It contains receptors for hormones such as estrogen and progesterone, which play a key role in sexual development and reproduction. The breast is also a source of sexual pleasure and can be an important symbol of femininity and motherhood.

It's worth noting that males also have breast tissue, although it is usually less developed than in females. Male breast tissue consists mainly of adipose tissue and does not typically contain functional mammary glands. However, some men may develop enlarged breast tissue due to conditions such as gynecomastia, which can be caused by hormonal imbalances or certain medications.

Genetic predisposition to disease refers to an increased susceptibility or vulnerability to develop a particular illness or condition due to inheriting specific genetic variations or mutations from one's parents. These genetic factors can make it more likely for an individual to develop a certain disease, but it does not guarantee that the person will definitely get the disease. Environmental factors, lifestyle choices, and interactions between genes also play crucial roles in determining if a genetically predisposed person will actually develop the disease. It is essential to understand that having a genetic predisposition only implies a higher risk, not an inevitable outcome.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

A heterozygote is an individual who has inherited two different alleles (versions) of a particular gene, one from each parent. This means that the individual's genotype for that gene contains both a dominant and a recessive allele. The dominant allele will be expressed phenotypically (outwardly visible), while the recessive allele may or may not have any effect on the individual's observable traits, depending on the specific gene and its function. Heterozygotes are often represented as 'Aa', where 'A' is the dominant allele and 'a' is the recessive allele.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Breast neoplasms in males refer to abnormal growths or tumors in the male breast tissue. These neoplasms can be benign (non-cancerous) or malignant (cancerous). While breast cancer is much less common in men than in women, it can still occur and should be taken seriously.

The most common type of breast cancer in men is invasive ductal carcinoma, which starts in the milk ducts and spreads to surrounding tissue. Other types of breast cancer that can occur in men include inflammatory breast cancer, lobular carcinoma, and Paget's disease of the nipple.

Risk factors for developing male breast cancer include age (most cases are diagnosed after age 60), family history of breast cancer, genetic mutations such as BRCA1 or BRCA2, radiation exposure, obesity, liver disease, and testicular conditions such as undescended testicles.

Symptoms of male breast neoplasms may include a painless lump in the breast tissue, skin changes such as dimpling or redness, nipple discharge, or a retracted nipple. If you notice any of these symptoms, it is important to consult with a healthcare professional for further evaluation and treatment.

The Founder Effect is a concept in population genetics that refers to the loss of genetic variation that occurs when a new colony is established by a small number of individuals from a larger population. This decrease in genetic diversity can lead to an increase in homozygosity, which can in turn result in a higher frequency of certain genetic disorders or traits within the founding population and its descendants. The Founder Effect is named after the "founding" members of the new colony who carry and pass on their particular set of genes to the next generations. It is one of the mechanisms that can lead to the formation of distinct populations or even new species over time.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

"Family Health" is not a term that has a single, widely accepted medical definition. However, in the context of healthcare and public health, "family health" often refers to the physical, mental, and social well-being of all members of a family unit. It includes the assessment, promotion, and prevention of health conditions that affect individual family members as well as the family as a whole.

Family health may also encompass interventions and programs that aim to strengthen family relationships, communication, and functioning, as these factors can have a significant impact on overall health outcomes. Additionally, family health may involve addressing social determinants of health, such as poverty, housing, and access to healthcare, which can affect the health of families and communities.

Overall, family health is a holistic approach to healthcare that recognizes the importance of considering the needs and experiences of all family members in promoting and maintaining good health.

Hereditary Nonpolyposis Colorectal Neoplasms (HNPCC), also known as Lynch Syndrome, is a genetic disorder that significantly increases the risk of developing colorectal cancer and other types of cancer. It is characterized by the mutation in genes responsible for repairing mistakes in the DNA replication process, specifically the mismatch repair genes (MMR).

HNPCC is typically inherited in an autosomal dominant manner, meaning that a person has a 50% chance of inheriting the mutated gene from an affected parent. The syndrome is associated with the development of colorectal cancer at a younger age, usually before 50 years old, and often in the proximal colon. Individuals with HNPCC also have an increased risk for other cancers, including endometrial, stomach, small intestine, ovary, kidney, brain, and skin (sebaceous gland tumors).

Regular surveillance and screening are crucial for early detection and management of colorectal neoplasms in individuals with HNPCC. This typically includes colonoscopies starting at a younger age and performed more frequently than in the general population. Genetic counseling and testing may also be recommended for family members who may have inherited the mutated gene.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Von Hippel-Lindau (VHL) disease is a rare genetic disorder characterized by the development of tumors and cysts in various parts of the body. It is caused by mutations in the VHL gene, which leads to the abnormal growth of blood vessels, resulting in the formation of these tumors.

The tumors associated with VHL disease can develop in several organs, including the eyes (in the form of retinal hemangioblastomas), the brain and spinal cord (in the form of cerebellar hemangioblastomas and spinal cord hemangioblastomas), the adrenal glands (in the form of pheochromocytomas or paragangliomas), the kidneys (in the form of clear cell renal cell carcinomas), and the pancreas (in the form of serous cystadenomas or neuroendocrine tumors).

Individuals with VHL disease are at risk for developing multiple tumors over their lifetime, and the severity of the disease can vary widely from person to person. The diagnosis of VHL disease is typically made through genetic testing, family history, and imaging studies to detect the presence of tumors. Treatment may involve surgical removal of the tumors, radiation therapy, or other interventions depending on the location and size of the tumors. Regular monitoring and follow-up are essential for individuals with VHL disease to manage their condition effectively.

The "age of onset" is a medical term that refers to the age at which an individual first develops or displays symptoms of a particular disease, disorder, or condition. It can be used to describe various medical conditions, including both physical and mental health disorders. The age of onset can have implications for prognosis, treatment approaches, and potential causes of the condition. In some cases, early onset may indicate a more severe or progressive course of the disease, while late-onset symptoms might be associated with different underlying factors or etiologies. It is essential to provide accurate and precise information regarding the age of onset when discussing a patient's medical history and treatment plan.

Carcinoma, ductal, breast is a type of breast cancer that begins in the milk ducts (the tubes that carry milk from the lobules of the breast to the nipple). It is called "ductal" because it starts in the cells that line the milk ducts. Ductal carcinoma can be further classified as either non-invasive or invasive, based on whether the cancer cells are confined to the ducts or have spread beyond them into the surrounding breast tissue.

Non-invasive ductal carcinoma (also known as intraductal carcinoma or ductal carcinoma in situ) is a condition where abnormal cells have been found in the lining of the milk ducts, but they have not spread outside of the ducts. These cells have the potential to become invasive and spread to other parts of the breast or body if left untreated.

Invasive ductal carcinoma (IDC) is a type of breast cancer that starts in a milk duct and then grows into the surrounding breast tissue. From there, it can spread to other parts of the body through the bloodstream and lymphatic system. IDC is the most common form of breast cancer, accounting for about 80% of all cases.

Symptoms of ductal carcinoma may include a lump or thickening in the breast, changes in the size or shape of the breast, dimpling or puckering of the skin on the breast, nipple discharge (especially if it is clear or bloody), and/or redness or scaling of the nipple or breast skin. However, many cases of ductal carcinoma are detected through mammography before any symptoms develop.

Treatment for ductal carcinoma depends on several factors, including the stage and grade of the cancer, as well as the patient's overall health and personal preferences. Treatment options may include surgery (such as a lumpectomy or mastectomy), radiation therapy, chemotherapy, hormone therapy, and/or targeted therapies.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

A mastectomy is a surgical procedure where the entire breast tissue along with the nipple and areola is removed. This is usually performed to treat or prevent breast cancer. There are different types of mastectomies, such as simple (total) mastectomy, skin-sparing mastectomy, and nipple-sparing mastectomy. The choice of procedure depends on various factors including the type and stage of cancer, patient's preference, and the recommendation of the surgical team.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Breast diseases refer to a wide range of conditions that affect the breast tissue. These can be broadly categorized into non-cancerous and cancerous conditions.

Non-cancerous breast diseases include:

1. Fibrocystic breast changes: This is a common condition where the breast tissue becomes lumpy, tender, and sometimes painful. It is caused by hormonal changes and is most common in women aged 20 to 50.
2. Mastitis: This is an infection of the breast tissue, usually occurring in breastfeeding women. Symptoms include redness, swelling, warmth, and pain in the affected area.
3. Breast abscess: This is a collection of pus in the breast tissue, often caused by bacterial infection. It can be painful and may require surgical drainage.
4. Fibroadenomas: These are benign tumors made up of glandular and fibrous tissue. They are usually round, firm, and mobile, and can be removed if they cause discomfort.
5. Intraductal papillomas: These are small, wart-like growths that occur in the milk ducts. They may cause nipple discharge, which can be bloody or clear.

Cancerous breast diseases include:

1. Breast cancer: This is a malignant tumor that starts in the breast tissue. It can spread to other parts of the body if left untreated. There are several types of breast cancer, including ductal carcinoma, lobular carcinoma, and inflammatory breast cancer.
2. Paget's disease of the nipple: This is a rare form of breast cancer that affects the skin of the nipple and areola. It can cause symptoms such as redness, itching, burning, and flaking of the nipple skin.
3. Phyllodes tumors: These are rare breast tumors that can be benign or malignant. They usually grow quickly and may require surgical removal.

It is important to note that not all breast lumps are cancerous, and many non-cancerous conditions can cause breast changes. However, any new or unusual breast symptoms should be evaluated by a healthcare professional to rule out serious conditions such as breast cancer.

Ovarian cancer, Breast cancer, Hereditary cancers, Rare cancers, Syndromes affecting the breast, Syndromes in females). ... Hereditary breast-ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal levels of breast cancer ... of the hereditary cancers. The hereditary factors may be proven or suspected to cause the pattern of breast and ovarian cancer ... Most hereditary breast-ovarian cancer syndromes are inherited in an autosomal dominant pattern. Biallelic and homozygous ...
... and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast ... cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and management of ovarian cancer and ... Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family ... Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome No authors listed. Obstet Gynecol. 2017 Sep. ...
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds ... Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds ... are well below the estimated risks of ovarian cancer published in the literature for similar patients. Breast cancers, which ... The Creighton University Hereditary Cancer Institute registry was searched for members of HBOC syndrome families who had ...
Sample Hospital and Medical Center Cancer Genetics Data Report on Potential Hereditary Breast and Ovarian Cancer Syndrome- ... Hereditary Breast and Ovarian Cancer Syndrome: A Guide for Patients and Their Families [DOC 966 KB] ... Hereditary Breast and Ovarian Cancer Syndrome: Fact Sheet for Healthcare Professionals [DOC 34.3 KB] ... Brochure on Talking to Your Family About Your Diagnosis of Hereditary Breast and Ovarian Cancer Syndrome [PPT - 302 KB] ...
Learn about a few family cancer syndromes here and what causes them. ... Certain types of cancer sometime seem to run in some families. ... Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Families ... Ovarian Cancer Risk Factors: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch syndrome, Peutz-Jeghers syndrome, ... Genetic Counseling and Testing for Breast Cancer Risk: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), BRCA1 and BRCA2 ...
... with a focus on hereditary breast and ovarian cancers and Lynch syndrome. ... This brief examines the role of public health initiatives for cancer genomics at the federal, state, and community level, ... Hereditary Breast and Ovarian Cancer Syndrome. HBOC most commonly involves pathogenic mutations in two breast cancer ... triple negative breast cancer,* ovarian cancer, cancer in both breasts, breast cancer in a male relative, or multiple relatives ...
Hereditary breast and/or ovarian cancer syndrome. Breast cancer (BC) is the most common cancer in women accounting for 25% of ... Hereditary breast and/or ovarian cancer syndrome?. Our RARE Concierge Services Guides are available to assist you by providing ... Hereditary breast and/or ovarian cancer syndrome. Get in touch with RARE Concierge.. Contact RARE Concierge ... website Syndromes Without A Name (SWAN) Australia facebook Syndromes Without A Name (SWAN) Australia instagram Syndromes ...
Hereditary Breast and Ovarian Cancer Syndrome -- WP 870. *HIV Long-Term Survivors -- WC 503.7 ...
The majority, but not all, of breast-ovary cancer families show linkage to this susceptibility locus, designated BRCA1. We ... The breast-ovary cancer-family syndrome is a dominant predisposition to cancer of the breast and ovaries which has been mapped ... Neoplastic Syndromes, Hereditary / genetics* * Netherlands / epidemiology * Ovarian Neoplasms / epidemiology * Ovarian ... breast cancer or ovarian cancer. All families contained at least one case of ovarian cancer. Overall, an estimated 76% of the ...
660,000-990,000 people living with hereditary breast and ovarian cancer. Lynch syndrome (hereditary colorectal cancer syndrome) ... Hereditary Breast and Ovarian Cancer. Since 2005, genetic testing for mutations in the breast cancer 1 (BRCA1) and breast ... Hereditary breast and ovarian cancer syndrome. Genetic referral and testing for individuals meeting personal and family history ... cancer 2 (BRCA2) genes, to identify women at increased risk for hereditary breast and ovarian cancer who could benefit from ...
While it cant be passed down, you can inherit genes that increase your risk for certain cancers. Learn how and why. ... Hereditary breast and ovarian cancer syndrome (HBOC): HBOC results from an inherited mutation in the BRCA1 or BRCA2 genes, ... family cancer syndrome. or hereditary cancer syndrome.. Family cancer syndromes are rare. Cancer will affect one-third. of ... hereditary cancers. Some cancers, such as breast and prostate cancer, tend to run in families. But not all cancers that run in ...
Hereditary Breast and Ovarian Cancer Syndrome By Anita Bennett MD , Health Tips , No Comments ... Hereditary Breast and Ovarian Cancer syndrome (HBOC) is a genetic condition that makes it more likely that a person will get ... October is Breast Cancer Awareness Month. I thought this would be a good time to discuss breast cancer in younger women. ... Breast Cancer in Younger Women By Anita Bennett MD , Health Tips , No Comments ...
Some of the questions from moms: Friend Just Diagnosed, Seeking a Dermatologist/Arlington, 24 And Might Have Breast Cancer!! ... advice and tips about cancer & treatment from moms communities. ... My family has hereditary breast ovarian cancer syndrome (HBOC) ... I Tested + for BRCA 2 Gene Mutation - Hereditary Breast Ovarian Cancer Syndrome. August 16, 2008 by Julie D. - Northbrook, IL ... Hi Mamas, I was just diagnosed with breast cancer and I have a daughter who will be four in a few weeks. She is r... ...
4. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden ... Hereditary breast and ovarian cancer syndrome.. ACOG Committee on Practice Bulletins. Gynecol Oncol; 2009 Apr; 113(1):6-11. ... 6. Prophylactic surgery in hereditary breast/ovarian cancer syndrome.. Levine DA; Gemignani ML. Oncology (Williston Park); 2003 ... Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome ...
Heterogeneity of Breast Cancer Genomes: Going Beyond Therapy to Risk Assessment and Precision Healthcare ... Hereditary Breast and Ovarian Cancer Syndrome--genetics. Precision Medicine. Treatment Outcome Publication Types: Lecture. ... She is a pioneer in cancer genetics whose body of work has focused on the molecular genetics of breast cancer progression. Her ... She is a pioneer in cancer genetics whose body of work has focused on the molecular genetics of breast cancer progression. Her ...
The strongest risk factors are advancing age and family history of ovarian and breast cancer. Women who have symptoms ... and measurement of biomarkers such as cancer antigen 125. If results are suspicious for ovarian cancer, the patient should be ... Ovarian cancer affects women of all ages but is most commonly diagnosed after menopause. More than 75% of affected women are ... Despite the low rate of early diagnosis, guidelines recommend against routine screening for ovarian cancer in average-risk ...
Ovarian cancer is hard to detect early because it may not cause early signs or symptoms. Its important to recognize the signs ... Hereditary Breast and Ovarian Cancer Syndrome (National Institutes of Health) * ClinicalTrials.gov: Ovarian Neoplasms (National ... Advances in Ovarian Cancer Research (National Cancer Institute) * Key Statistics about Ovarian Cancer (American Cancer Society) ... Ovarian Cancer Statistics (National Cancer Institute) * Whats New in Ovarian Cancer Research and Treatment? (American Cancer ...
A small number of pancreatic cancer cases are thought to be linked to hereditary cancer syndromes. Learn more about the ... Hereditary breast and ovarian cancer syndrome. Inherited mutations in the BRCA1 and BRCA2 genes lead to a condition called ... all cancers we treat > pancreatic cancer > risk factors > hereditary cancer syndromes and pancreatic cancer>Hereditary cancer ... prostate and male breast cancers. Hereditary breast cancer. Another type of hereditary breast cancer, caused by mutations in ...
Hereditary breast ovarian cancer syndrome. 1 test. Holoprosencephaly sequence. 1 test. Hyperhomocysteinemia. 1 test. ... Breast-ovarian cancer, familial, susceptibility to, 1. 1 test. Breast-ovarian cancer, familial, susceptibility to, 2. 1 test. ... Breast and colorectal cancer, susceptibility to. 1 test. ... Dubin-Johnson syndrome. 1 test. Familial cancer of breast. 1 ...
Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome ... Cancer Genome Altas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011) ... COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011) ... Instituto de Biologia Molecular y Celular del Cancer, Centro de Investigacion del Cancer/IBMCC (CSIC-USAL), Institute of ...
Tags: brca, brca1, brca2, Breast, Cancer, Hereditary, inicial, Initial, mama, Ovarian, ovario, Screening, sindrome, Syndrome ... Initial Screening for Hereditary Breast and Ovarian Cancer Syndrome. 4 February, 2016 Guillermo Firman ... The initial screening for hereditary breast and ovarian cancer syndrome should include specific questions about the patients ... Revised Criteria for Hereditary Non-Polyposis Colorectal Cancer (Lynch Syndrome). 25 February, 2009 Guillermo Firman ...
... of ovarian cancers are hereditary. As such, patients with a history suggestive of a hereditary breast-ovarian cancer syndrome ( ... 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009 Apr. 113(4):957-66. [QxMD MEDLINE Link]. ... 15, 16, 17] All include women with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer at any ... Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized ...
The referrals for Hereditary cancer syndromes were dominated by: Hereditary breast and ovarian cancer; Lynch syndrome, and ... The patients were divided into different groups, based on inquiry type: Hereditary cancer syndromes, and Other genetic ... Zillacus E. Evaluating Telehealth Cancer Genetic Counselling; Impact on genetic counselling outcomes, patient satisfaction and ... Zilliacus EM, Meiser B, Lobb EA, Kirk J, Warwick L. Womens experience of telehealth cancer genetic counselling. J Genet Couns. ...
Our name stands for Comprehensive Assessment, Treatment, and Prevention of Cancers with Hereditary Predispositions. ... When youre at high risk for cancer because of the genes you were born with, you need as much support as possible. You can get ... Females at higher risk for ovarian and endometrial cancers, Lynch syndrome, and hereditary breast and ovarian cancer (HBOC) ... Whats a hereditary cancer syndrome?. A hereditary cancer syndrome is caused by gene mutations that your parents passed down to ...
Hereditary gynecologic cancer syndromes: in particular hereditary breast and ovarian cancer and Lynch syndromes. ... Cancer Surgery. * Cancer, Cancer research, Clinical trials and research, Cytoreductive surgery, Gynecologic cancer, ... Hereditary gynecologic cancer syndromes. Speaker and instructor for a non-profit organization Bright Pink - national non-profit ... organization that focuses on prevention and early detection of breast and ovarian cancer in all young women and in addition ...
... is a hereditary gastric cancer syndrome associated with CDH1 and CTNNA1 genes. Learn about HDGCs cancer risks and management. ... This phenomenon has also been seen with other hereditary cancer syndromes, like hereditary breast and ovarian cancer and Lynch ... Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant hereditary cancer syndrome that increases an individuals ... Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer ...
... of ovarian cancer cases, and those with germline pathogenic variants have an odds ratio between 4 and 40 for developing ovarian ... of the population carries genetic variants that lead to conditions that include hereditary breast and ovarian cancer and Lynch ... carries genetic variants that lead to conditions that include hereditary breast and ovarian cancer and Lynch syndrome. These ... Unfortunately, most individuals with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and racial ...
... followed by results for hereditary breast and ovarian cancer syndrome, and Lynch syndrome. ... Germany to Test Genomics-Based Precision Medicine for Cancer, Rare Disease in National Pilot Project Premium ...
... breast and ovarian cancers), and p53 mutations resulting in Li-Fraumeni syndrome (multiple cancers including breast, colorectal ... both linked to hereditary nonpolyposis colon cancer) cause defective DNA repair. Also, recent cancer epidemiology and ... Also, women at high risk for breast cancer may benefit from chemopreventive intervention that controls breast cell ... The letter of intent is to be sent to: Gary J. Kelloff, M.D. Division of Cancer Prevention and Control National Cancer ...

No FAQ available that match "hereditary breast and ovarian cancer syndrome"

No images available that match "hereditary breast and ovarian cancer syndrome"